Affimed Immuno-oncology 2019: ROCK Platform & Innate Cell Engagers

Affimed presents its proprietary ROCK® platform and approach to advancing immuno-oncology through innate cell engagers targeting hematologic and solid tumors. The company highlights its clinical-stage programs, strategic partnerships with Genentech and Merck, and its position as the only company with a clinical-stage innate cell engager leveraging CD16A target capabilities.